In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 Eur...

Descripción completa

Detalles Bibliográficos
Autores: Quindós G., Miranda-Cadena K., San-Millán R., Borroto-Esoda K., Cantón E., Linares-Sicilia M.J., Hamprecht A., Montesinos I., Tortorano A.M., Prigitano A., Vidal-García M., Marcos-Arias C., Guridi A., Sanchez-Reus F., Machuca-Bárcena J., Rodríguez-Iglesias M.A., Martín-Mazuelos E., Castro-Méndez C., López-Soria L., Ruiz-Gaitán A., Fernandez-Rivero M., Lorenzo D., Capilla J., Rezusta A., Pemán J., Guarro J., Pereira J., Pais C., Romeo O., Ezpeleta G., Jauregizar N., Angulo D., Eraso E.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p12055
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12055
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131270958&doi=10.3389%2ffcimb.2022.906563&partnerID=40&md5=b29016e192653bbe0e901d9afdb2825a
Access Level:acceso abierto
Palabra clave:antifungal testing
antifungal resistance
Candida
ibrexafungerp
SCY-078
EUCAST
caspofungin
micafungin
id ES_bbcef373c704dda8ffe644e27d4d461d
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p12055
network_acronym_str ES
network_name_str España
repository_id_str
spelling In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European StudyQuindós G.Miranda-Cadena K.San-Millán R.Borroto-Esoda K.Cantón E.Linares-Sicilia M.J.Hamprecht A.Montesinos I.Tortorano A.M.Prigitano A.Vidal-García M.Marcos-Arias C.Guridi A.Sanchez-Reus F.Machuca-Bárcena J.Rodríguez-Iglesias M.A.Martín-Mazuelos E.Castro-Méndez C.López-Soria L.Ruiz-Gaitán A.Fernandez-Rivero M.Lorenzo D.Capilla J.Rezusta A.Pemán J.Guarro J.Pereira J.Pais C.Romeo O.Ezpeleta G.Jauregizar N.Angulo D.Eraso E.antifungal testingantifungal resistanceCandidaibrexafungerpSCY-078EUCASTcaspofunginmicafunginBackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida.Frontiers Media S.A.2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12055https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131270958&doi=10.3389%2ffcimb.2022.906563&partnerID=40&md5=b29016e192653bbe0e901d9afdb2825aFrontiers in Cellular and Infection MicrobiologyISSN: 22352988reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p120552026-06-14T12:41:47Z
dc.title.none.fl_str_mv In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
title In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
spellingShingle In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
Quindós G.
antifungal testing
antifungal resistance
Candida
ibrexafungerp
SCY-078
EUCAST
caspofungin
micafungin
title_short In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
title_full In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
title_fullStr In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
title_full_unstemmed In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
title_sort In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
dc.creator.none.fl_str_mv Quindós G.
Miranda-Cadena K.
San-Millán R.
Borroto-Esoda K.
Cantón E.
Linares-Sicilia M.J.
Hamprecht A.
Montesinos I.
Tortorano A.M.
Prigitano A.
Vidal-García M.
Marcos-Arias C.
Guridi A.
Sanchez-Reus F.
Machuca-Bárcena J.
Rodríguez-Iglesias M.A.
Martín-Mazuelos E.
Castro-Méndez C.
López-Soria L.
Ruiz-Gaitán A.
Fernandez-Rivero M.
Lorenzo D.
Capilla J.
Rezusta A.
Pemán J.
Guarro J.
Pereira J.
Pais C.
Romeo O.
Ezpeleta G.
Jauregizar N.
Angulo D.
Eraso E.
author Quindós G.
author_facet Quindós G.
Miranda-Cadena K.
San-Millán R.
Borroto-Esoda K.
Cantón E.
Linares-Sicilia M.J.
Hamprecht A.
Montesinos I.
Tortorano A.M.
Prigitano A.
Vidal-García M.
Marcos-Arias C.
Guridi A.
Sanchez-Reus F.
Machuca-Bárcena J.
Rodríguez-Iglesias M.A.
Martín-Mazuelos E.
Castro-Méndez C.
López-Soria L.
Ruiz-Gaitán A.
Fernandez-Rivero M.
Lorenzo D.
Capilla J.
Rezusta A.
Pemán J.
Guarro J.
Pereira J.
Pais C.
Romeo O.
Ezpeleta G.
Jauregizar N.
Angulo D.
Eraso E.
author_role author
author2 Miranda-Cadena K.
San-Millán R.
Borroto-Esoda K.
Cantón E.
Linares-Sicilia M.J.
Hamprecht A.
Montesinos I.
Tortorano A.M.
Prigitano A.
Vidal-García M.
Marcos-Arias C.
Guridi A.
Sanchez-Reus F.
Machuca-Bárcena J.
Rodríguez-Iglesias M.A.
Martín-Mazuelos E.
Castro-Méndez C.
López-Soria L.
Ruiz-Gaitán A.
Fernandez-Rivero M.
Lorenzo D.
Capilla J.
Rezusta A.
Pemán J.
Guarro J.
Pereira J.
Pais C.
Romeo O.
Ezpeleta G.
Jauregizar N.
Angulo D.
Eraso E.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv antifungal testing
antifungal resistance
Candida
ibrexafungerp
SCY-078
EUCAST
caspofungin
micafungin
topic antifungal testing
antifungal resistance
Candida
ibrexafungerp
SCY-078
EUCAST
caspofungin
micafungin
description BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12055
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131270958&doi=10.3389%2ffcimb.2022.906563&partnerID=40&md5=b29016e192653bbe0e901d9afdb2825a
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12055
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131270958&doi=10.3389%2ffcimb.2022.906563&partnerID=40&md5=b29016e192653bbe0e901d9afdb2825a
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv Frontiers in Cellular and Infection Microbiology
ISSN: 22352988
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418058236297217
score 15,811543

Similares en LA Referencia